If Geron's current CEO and most of its board members are expelled and replaced with people having better foresight and are sharper, I think the SP will jump high as institutional investors plunge in and the shorts start covering. The problem is not what is going on at the trial front, it's the stupid management that doesn't inspire optimism to institutional guys..
eoi, you are right; but, it appears, as Scarlett announced some time back, that the company IS looking for acquiring a compatible product or an outfit. I think it is best for the company to go after the Patent 615, and, hence, get Gryaznov on board. Perhaps that is what JNJ also wishes so that it can absorb Geron ultimately into its Janssen subsidiary. I hope Scarlett and HUh looks for such a step and not foolishly buy an unknown and questionable product or outfit.
If he made right decisions and if he is such a great guy, why is the Street and institutions not jumping in this stock and why the short volume is still stubbornly unchanged after almost a year since the JNJ deal is announced? Do you have answers to that? It is YOUR perception that he is great, not mine and many others'!! Just open your eyes and give credence to what others have to say!!
Greg, the deal can be a mixture of cash and securities. JNJ may also participate in financing if they are allowed a stake, which is more likely. I think the latter may be in the plan and Tefferi may also have blessed such a deal, if any. The problem is that the Geron management doesn't give any clue to its shareholders and that, I suspect, is because the bozos at Geron may be looking at their gain rather than the shareholders. Scarlett's greed for $6M compensation from an outfit with a staff of only 21 and not a penny yet in profit is indicative of what these guys may have in their mind. And, I think that may also be the worry of institutional investors who watch much more closely than TomDicken&Harrys like us.
Who is the bozo who keeps marking downthumbs for all certain posts (except the one by IrishTrader!) without understanding the content of the posts?!! Must be a disgruntled idiot!!
You are missing an important distinction here between solid-tumor cancers and hematologic cancers. IMET is effective primarily in the latter, not in the former. That shows that the treatment for the two types is not the same. Why?!!
Also, your contention that GERN SP is falling due to this Mayo research is utterly senseless, first because the Mayo research is not yet sent for licensing that takes years (it is still in its infancy) and secondly because it's due to the WS fear that the bozos at Geron may misuse the JNJ money in acquisition of a worthless product or outfit. The Street is waiting to hear from the Geron management about their plan to do so and so far there is no word. Perhaps the Street doesn't trust Scarlett-Huh team to handle any potential growth of the company since they screwed up the stem-cell deal and also the ET/PV trials, besides many other missteps.
Earfool, the urgent need is not just based on Tefferi's work!! It is based on the current practice. Tefferi's statement above doesn't include the fact that the stem-cell treatment does have several serious potential side effects and do not succeed in most cases. This is what I learned from my recent visit to Sloan Kettering in Manhattan. Yes, the need for IMET to go in the market is urgent and I am glad that it is being taken over fully by Janssen from the hands of the bozos at Geron.
for Geron, if it doesn't want to merge with JNJ, is to buy the outfit where Gryaznov currently works and then pour money it gets from JNJ in further development of Patent 615. Of course, the board will have to fire Scarlett and replace him with another sharp guy and assign Gryaznov the position of Chief Scientific Officer. This will make not only JNJ happy but also the Wall Sttreet and, also, the staff.
IWS, it's not just success of IMET, it's also the bloody management action that will control the GERN share price. If the bozos at Geron decide to waste the money in buying worthless product or an outfit, they can undo all the glory IMET does to the company!! First and foremost, JNJ must take control of Geron, replace all those bozos at Geron with really sharp guys and get IMET in the global market.
Desperate looser, aren't you?!! Don't worry, worse days are ahead for you! But, you just live in the past and remain in the mud!!
Take monkeys on a ride and then, suddenly, drop them on the ground!! Are you hurt bad?!!!!! You wanted easy money, isn't it? Then, bear the pain too!!! how many times you were used like a toy? Did you learn anything from the experience?!! OR are you the same idiot?!!!
I agree. The problem with monkey traders is that they do not have their own brain capacity and all they do is looking through tainted glasses. It's not their cup of tea to see what you just saw!! I will just ignore what the monkeys say about what you say. I think your investment will be good and you will reap good rewards in about a couple of years.
How can you ever be smart?!! The grant is a recognition of the technology by a reputed organization, and the SP ups and downs are the creations of Wall Street casino players!! Can't you see the difference? Well, perhaps, it's beyond your ability to see. You should be just sticking to your charts like all monkey traders do!!
To-morrow, GERN should experience an upswing, not a selloff!! Diggerguy, do not be too greedy like Scarlett to dig deeper into your short position!!
Tell me how you feel comparing Geron under Scarlett and Ocata under Wotton a few months from now and again a couple of years from now!! I hope your love for Scarlett doesn't disappoint you!! It is my money and neither Scarlett's nor Wotton's; but, going by the facts as of to-day, I do not regret having more faith in Ocata than in Geron. While IMET and RPE cell technology are both breakthrough products, both in Ph 2 trials, it's Scarlett's greed and lack of foresight, including that of Geron board that pose serious questions about how they take the company forward. Greedy CEOs are not interested in what is good for shareholders; they work for themselves. I simply hope Scarlett comes around and proves himself worthy of my confidence in my investment in the company. My fingers are crossed as I still remain invested in Geron solely due to future of IMET (now in the hands of Janssen). But, reality is what one should consider and not blind faith. Good luck.
Get my point and please don't be stupid to knit pick.